Haematological tumours research encompass a diverse group of blood cancers that originate in the bone marrow, lymph nodes, and other components of the hematopoietic system. This field is vital to biomedical and clinical sciences as it addresses diseases that affect millions worldwide, such as leukemia, lymphoma, and myeloma. Research covers the biology, diagnosis, treatment, and prognosis of various hematologic malignancies. JoVE Visualize enriches access to this research by pairing relevant PubMed articles with JoVE’s experiment videos, helping researchers and students grasp complex methodologies and pivotal findings with clarity.
Key Methods & Emerging Trends
Established Methods in Haematological Tumour Research
Core techniques in haematological tumour research include flow cytometry for immunophenotyping, cytogenetic analysis to detect chromosomal abnormalities, and molecular assays such as PCR and next-generation sequencing for identifying genetic mutations. These methods are essential for diagnosing the list of hematologic malignancies and understanding their pathogenesis. Histopathological examination remains a cornerstone for tumor classification and assessing characteristics linked to aggressiveness or treatment response. Such established approaches provide robust platforms for investigating hematologic cancer symptoms and improving patient outcomes.
Emerging and Innovative Techniques
Innovative methods are rapidly advancing the study of haematological tumours, including single-cell RNA sequencing to examine tumor heterogeneity and clonal evolution in unprecedented detail. Liquid biopsies analyzing circulating tumor DNA offer minimally invasive insights into disease progression and therapeutic resistance. Additionally, CRISPR-Cas9 gene editing is opening new avenues for functional genomic studies and potential targeted therapies. Integrating artificial intelligence into diagnostic imaging and data analysis also enhances detection and prognosis predictions, addressing critical questions such as which type of blood cancer is most dangerous and improving survival rate assessments.